A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? | Oncotarget
CPI-613 Supplier | CAS 95809-78-2 | Focus Biomolecules
Devimistat - Wikipedia
Predictive targeting of mitochondrial metabolism in Acute Myeloid Leukemia patients with a lipoic acid analog | medRxiv
A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma
Devimistat – Drug Approvals International
CPI-613 (Devimistat) | ≥99%(HPLC) | Dehydrogenase Inhibitor | AdooQ®
Cancers | Free Full-Text | The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
Cancers | Free Full-Text | The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
A combination of CPI-613 and chloroquine significantly suppressed tumor... | Download Scientific Diagram
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study | Future Oncology
The Pyruvate Dehydrogenase Complex in Cancer: Implications for the Transformed State and Cancer Chemotherapy | IntechOpen
Selectively Targeting Metabolism in Mitochondria In Cancer Cells | Cancer Biology
Devimistat - Wikipedia
An integrated in vivo and in silico analysis of the metabolism disrupting effects of CPI-613 on embryo-larval zebrafish (Danio rerio) - ScienceDirect
The Pyruvate Dehydrogenase Complex in Cancer: Implications for the Transformed State and Cancer Chemotherapy | IntechOpen
The Mitochondrion as an Emerging Therapeutic Target in Cancer: Trends in Molecular Medicine
Frontiers | Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio | Oncology
A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process | SpringerLink
Predictive targeting of mitochondrial metabolism in Acute Myeloid Leukemia patients with a lipoic acid analog | medRxiv
Devimistat (CPI-613) | デヒドロゲナーゼ 阻害剤
Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation | Scientific Reports
